Trachoma Treatments

Find Trachoma Treatments

Generic Name

Minocycline

Brand Names

Amzeeq, Arestin, Emrosi, Minocin, ZILXI

FDA approval date: December 30, 1991

Classification: Tetracycline-class Drug

Form: Injection, Aerosol, Tablet, Powder, Capsule

What is Amzeeq (Minocycline)?

AMZEEQ is indicated for the topical treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in adults and pediatric patients 9 years of age and older. Limitations of Use This formulation of minocycline has not been evaluated in the treatment of infections. To reduce the development of drug-resistant bacteria as well as to maintain the effectiveness of other antibacterial drugs, AMZEEQ should be used only as indicated [ see Warnings and Precautions.

Approved To Treat

Top Global Experts

Min J. Wu

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Tired of the same old research?

Check Latest Advances

Related Clinical Trials

Treatment of Rheumatoid Arthritis With Disease-modifying Antirheumatic Drugs (DMARDs): Predictors of Response

Who is this study for: Patients with early rheumatoid arthritis

Enrollment Status: Recruiting

Publish Date: June 17, 2026

Intervention Type: Drug

Study Drug: Methotrexate

Study Phase: Phase 3

Summary: Rheumatoid arthritis (RA) is a common disease with approximately 1% prevalence. RA is also a chronic, progressive disease with no cure. Current treatment goals are to minimize pain, limit joint damage, and prevent loss of function. Drugs used to treat RA include non-steroidal anti-inflammatory drugs (NSAIDS), glucocorticoids, and disease-modifying anti-rheumatic drugs (DMARDs), including biologics...

Safety and Efficacy of Adjunctive Minocycline After Successful Endovascular Thrombectomy Recanalization for Acute Anterior Circulation Large Vessel Occlusion - A Multicenter, Prospective, Double-blind, Randomized Trial

Enrollment Status: Recruiting

Publish Date: May 27, 2026

Intervention Type: Drug

Study Phase: Phase 2/Phase 3

Summary: Endovascular thrombectomy (EVT) improves outcomes in patients with acute large vessel occlusion (LVO). However, despite successful recanalization rates exceeding 80%, fewer than 50% of patients achieve favorable functional outcomes at 90 days, indicating a high rate of futile recanalization. Potential mechanisms include no-reflow, reperfusion injury, and microcirculatory dysfunction, which are clo...

Safety and Efficacy of Adjunctive Minocycline After Successful Endovascular Thrombectomy Recanalization for Acute Posterior Circulation Arterial Occlusion - A Multicenter, Prospective, Double-blind, Randomized Trial

Enrollment Status: Recruiting

Publish Date: May 22, 2026

Intervention Type: Drug

Study Phase: Phase 2/Phase 3

Summary: Acute ischemic stroke (AIS) is a leading cause of mortality and long-term disability worldwide. Among these, stroke caused by large vessel occlusion (LVO) are associated with particularly poor outcomes. Multiple randomized controlled trials have demonstrated that endovascular thrombectomy (EVT) significantly improves clinical outcomes in patients with acute LVO and is recommended as the standard o...

View All Clinical Trials